For instance, ARID1A alterations are associated with better outcomes after immunotherapy across histologies; PBRM1 alterations correlate with responsiveness to immunotherapy in some publications but not in others; and alterations in another chromatin remodeling gene — SMARCA4 — are associated with responsiveness of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), to immunotherapy (27, 35, 44). The gene discussed is ARID1A; the disease is ovarian small cell carcinoma.